Alexey Surov

Prof. Alexey Surov

Department of Radiology and Nuclear Medicine, Otto-von-Guericke University Magdeburg, Leipziger Str 44, 39112 Magdeburg, Germany
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ASAlexey Surov
Alexey Surov
HMHans Jonas Meyer
Hans Jonas Meyer
AWAndreas Wienke
Andreas Wienke
Https://doi.org/10.18632/oncotarget.17752 Alexey Surov, Hans Jonas Meyer, Andreas Wienke

12 August 2009 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
ASAlexey Surov
Alexey Surov
AWAndreas Wienke
Andreas Wienke
JCJustin M. Carter
Justin M. Carter
DSDietrich Stoevesandt
Dietrich Stoevesandt
CBCurd Behrmann
Curd Behrmann
MBMichael Buerke
Michael Buerke

26 August 2009 in European Radiology
Verified
Journal Article
Closed access
PDF file
ASAlexey Surov
Alexey Surov
MHMichael Hainz
Michael Hainz
HHHans-Jürgen Holzhausen
Hans-Jürgen Holzhausen
DADirk Arnold
Dirk Arnold
MKMichaela Katzer
Michaela Katzer
CBCurd Behrmann
Curd Behrmann

19 June 2022 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
ASAlexey Surov
Alexey Surov
AWAndreas Wienke
Andreas Wienke
Background: The purpose of the present meta‐analysis was to analyze the prevalence of sarcopenia on staging computed tomography (CT) in patients with different malignant solid tumors and in different oncologic settings based on a large sample.Methods: MEDLINE, Cochrane, and SCOPUS literature databases were screened for prevalence of sarcopenia in oncologic patients up to December 2021. Overall, 280 studies met the inclusion criteria. The methodological quality of the involved studies was checked according to the Quality Assessment of Diagnostic Studies instrument. The meta‐analysis was undertaken by using RevMan 5.4 software. DerSimonian and Laird random‐effects models with inverse‐variance weights were used.Results: The included 280 studies comprised 81,814 patients with different tumors. The prevalence of sarcopenia over all included studies was 35.3%. A prevalence of sarcopenia >50% was identified in esophageal cancer, urothelial cancer, cholangiocarcinoma, prostate cancer, sarcomas, and thyroid cancer. In head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer, the prevalence of sarcopenia varied between 35% and 50%. In colorectal cancer, gastric cancer, hepatocellular cancer, and breast cancer, the prevalence of low skeletal muscle mass was <35%. In curative setting, the prevalence of sarcopenia was 39.6% and in palliative setting, it was 49.2% (P< 0.001).Conclusions: Sarcopenia is a frequent condition in oncology with a prevalence of 35.3%. The prevalence of sarcopenia is higher in palliative setting vs curative setting. The prevalence of sarcopenia is also different in different tumors.

24 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ASAlexey Surov
Alexey Surov
HMHans Jonas Meyer
Hans Jonas Meyer
AWAndreas Wienke
Andreas Wienke
Https://doi.org/10.18632/oncotarget.20406 Alexey Surov, Hans Jonas Meyer, Andreas Wienke

1 June 2012 in British Journal of Radiology
Verified
Journal Article
Closed access
ASAlexey Surov
Alexey Surov
HHH-J Holzhausen
H-J Holzhausen
AWA Wienke
A Wienke
JSJ Schmidt
J Schmidt
CTC Thomssen
C Thomssen
RSR-P Spielmann
R-P Spielmann
Objectives: The purpose of this study was to determine the prevalence, clinical signs and radiological features of breast lymphoma. Methods: This is a retrospective review of 36 patients with breast lymphoma (22 primary and 14 secondary). 35 patients were female and 1 was male; their median age was 65 years (range 24–88 years). In all patients, the diagnosis was confirmed histopathologically. Results: The prevalence of breast lymphoma was 1.6% of all identified cases with non-Hodgkin lymphoma and 0.5% of cases with breast cancer. B-cell lymphoma was found in 94% and T-cell lymphoma in 6%. 96 lesions were identified (2.7 per patient). The mean size was 15.8±8.3 mm. The number of intramammary lesions was higher in secondary than in primary lymphoma. The size of the identified intramammary lesions was larger in primary than in secondary lymphoma. Clinically, 86% of the patients presented with solitary or multiple breast lumps. In 14%, breast involvement was diagnosed incidentally during staging examinations....